🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Late-stage data show durability of response for Spark's Luxturna

Published 11/13/2017, 02:07 PM
© Reuters.  Late-stage data show durability of response for Spark's Luxturna
ONCE_old
-
  • Three-year follow-up data from the Phase 3 study evaluating Spark Therapeutics' (ONCE -0.7%) LUXTURNA (voretigene neparvovec) in patients with biallelic RPE65-mediated inherited retinal disease showed a sustained treatment benefit. The results were presented at the AAO Retina Subspecialty Day.
  • At year 3, patients receiving one-time treatment with the gene therapy maintained the average improvement in functional vision observed at the original year 1 time point and the year 2 time point in the crossover group.
  • FDA approval is expected no later than January 12, 2018 after a positive Ad Com vote on October 12.
  • Previously: Spark Therapeutics resumes trading up 6.4% (Oct. 12)
  • Now read: Nektar's gain Calithera's pain on Opdivo combo treatments; shares down 15%


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.